Esperion Therapeutics has a more favorable investment profile than Clearmind Medicine due to higher potential upside, lower volatility, and institutional ownership.
Esperion Therapeutics (ESPR) is considered a more favorable investment than Clearmind Medicine (CMND) based on factors such as higher potential upside (332.10%), consensus target price ($9.33), institutional ownership (47.4% held by institutional investors), and lower volatility (beta of 0.89, 11% less volatile than S&P 500). In comparison, Clearmind Medicine has a higher volatility (beta of 1.06, 6% more volatile than S&P 500) and has a net loss of -$8.62M.
June 01, 2024
5 Articles